Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 03:54 am EDT
Share
Henan Lingrui Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 2,053.04 million compared to CNY 1,749.41 million a year ago. Revenue was CNY 2,053.04 million compared to CNY 1,749.41 million a year ago. Net income was CNY 326.73 million compared to CNY 269.57 million a year ago. Basic earnings per share from continuing operations was CNY 0.585 compared to CNY 0.475 a year ago. Diluted earnings per share from continuing operations was CNY 0.579 compared to CNY 0.475 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.